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CASE REPORT
Mobilized peripheral blood hematopoietic stem
cells (PBSCs) have become the main source for
autologous and allogeneic hematopoietic stem
cell transplantation in patients with various hema-
tologic malignancies and solid tumors. However,
a number of patients fail to yield sufficient PBSCs
for successful engraftment. There is a significant
correlation between the quantity of re-infused
CD34+ cells and sustained engraftment. Many risk
factors account for poor mobilization,1–6 but the
influence of viral infection, which occurs espe-
cially in the neutropenic phase of mobilization
chemotherapy, has rarely been reported. Here, we
report a case of relapsed diffuse large B-cell lym-
phoma (DLBCL) with poor PBSC mobilization.
This may have been associated with reactivation
of herpes zoster virus during the neutropenic
phase of mobilization chemotherapy. We obtained
a sufficient number of PBSCs during remobiliza-
tion using the same mobilization regimen.
Case Report
A 54-year-old man with primary extranodal
DLBCL of the right tibia initially presented with
painful swelling of the right lower leg and a right
tibial osteolytic tumor. He showed complete re-
mission after eight courses of standard CHOP
(cyclophosphamide, doxorubicin, vincristine and
prednisolone) chemotherapy and subsequent
6500 cGy radiotherapy. Relapsed DLBCL over the
radius, ulna and sternum, without bone marrow
involvement, was found 13 months later, and a
Herpes Zoster Infection Associated with Poor
Peripheral Blood Hematopoietic Stem Cell
Mobilization
Yi-Chang Liu,1 Po-Liang Lu,2 Hui-Hua Hsiao,1 Huei-Jen Tsai,1 Ta-Chih Liu,1 Sheng-Fung Lin1*
The efficacy of peripheral blood hematopoietic stem cell (PBSC) harvest is important for successful autol-
ogous transplantation. The impact of viral infection on PBSC mobilization has rarely been reported. Here,
we report a patient with relapsed diffuse large B-cell lymphoma who experienced disseminated cutaneous
herpes zoster infection during the neutropenic phase of PBSC mobilization. A markedly reduced number
of PBSCs was initially harvested (1.72 × 106/kg, 77.2% reduction), followed by a sufficient number
(7.55 × 106/kg) during remobilization with the same mobilization regimen when herpes zoster infection
had subsided. Because of the temporal association, we suggest that herpes zoster infection is a risk factor
for poor PBSC mobilization, and remobilization with the same regimen is feasible. [J Formos Med Assoc
2008;107(12):958–960]
Key Words: autologous peripheral blood stem cell transplantation, hematopoietic stem cell transplantation,
herpes virus, mobilization
©2008 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Divisions of 1Hematology-Oncology and 2Infectious Disease, Department of Internal Medicine, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan.
Received: June 14, 2007
Revised: September 20, 2007
Accepted: November 6, 2007
*Correspondence to: Dr Sheng-Fung Lin, Division of Hematology-Oncology,
Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou
1st Road, Kaohsiung 807, Taiwan.
E-mail: shlin@kmu.edu.tw
H. zoster and poor PBSC mobilization
J Formos Med Assoc | 2008 • Vol 107 • No 12 959
partial response was noted after two courses of
salvage chemotherapy with MINE (mitoxantrone,
ifosfamide and etoposide). In preparation for
high-dose chemotherapy with autologous PBSC
transplantation, PBSCs were mobilized with a con-
ventional regimen of cyclophosphamide (4 g/m2)
and granulocyte colony-stimulating factor (G-CSF;
5 μg/kg/day since nadir white blood cell count
[WBC]), 7 weeks after the latest chemotherapy
regimen. However, 8 days after chemotherapy,
during the neutropenic phase (WBC, 190/μL) of
mobilization chemotherapy, he developed painful
vesiculopapular eruptions on an erythematous
base over the unilateral T10 dermatome. Skin
biopsy revealed intraepidermal vesicles with inter-
cellular edema, multinucleated giant keratinocytes
with steel grey nuclei, and margination of chro-
matin. All cultures for bacteria and fungi were
negative. Testing for herpes zoster virus IgM was
positive when a skin rash developed. Herpes zoster
and herpes simplex virus IgG levels were < 1:4 and
1:32, respectively, when the skin rash developed.
Both titers were 1:16 at the convalescent stage
when skin lesions subsided. Intravenous acyclovir
was initiated 10 days after chemotherapy and the
skin lesions subsided gradually 3 weeks later.
PBSCs were harvested as scheduled by three
apheresis procedures when WBC approached
1000/μL (12 days after cyclophosphamide). How-
ever, inadequate CD34+ cells were harvested
(1.72 × 106/kg). CD34+ cell percentages in periph-
eral blood were 0.10%, 0.20% and 0.14% on 3
consecutive days.
Remobilization was performed 8 weeks later
with the same mobilization regimen, when the
patient was free of febrile neutropenia and skin
lesions. PBSCs were harvested again by three
apheresis procedures when WBC approached
1000/μL (11 days after cyclophosphamide). The
total number of CD34+ cells was 7.55 × 106/kg.
CD34+ cell percentages in peripheral blood were
0.36%, 0.62% and 0.56% on 3 consecutive days.
Compared with the recruited CD34+ cell
amount, there was a 77.2% reduction in CD34+
cells (1.72 vs. 7.55 × 106/kg) when the patient
showed evidence of active herpes zoster infection.
The characteristics of the two consecutive courses
of PBSC harvest are shown in the Table.
Discussion
Autologous PBSC transplantation following mye-
loablative therapy is widely used for various
hematologic malignancies and solid tumors. The
goal of PBSC mobilization is to obtain at least
2 × 106/kg CD34+ cells to ensure rapid and sus-
tained engraftment. There are many risk factors
that are correlated with poor mobilization. Type
of malignancy, different mobilization regimens,
interval between diagnosis and mobilization,
number of prior chemotherapy courses, prolonged
exposure to alkylating agents, lower WBC and
platelet count, old age, disease status, and the in-
terval between recent chemotherapy and mobi-
lization are known to influence PBSC yield.1–6 In
our case, the two harvests had a similar interval
between the latest chemotherapy and mobiliza-
tion chemotherapy (7 vs. 8 weeks) and a similar
initial WBC and platelet count. However, the first
Table. Comparison of peripheral blood hematopoietic stem cell (PBSC) harvests
First harvest Second harvest
Mobilization regimen CY + G-CSF CY + G-CSF
Number of apheresis procedures 3 3
Interval between latest chemotherapy and mobilization chemotherapy (wk) 7 8
WBC before mobilization chemotherapy (per μL) 5190 4360
Time from CY to PBSC harvest (d) 12 11
CD34+ cell percentage in peripheral blood during 3 consecutive days of apheresis 0.10/0.20/0.14 0.36/0.62/0.56
Total CD34+ cells (× 106/kg) 1.72 7.55
CY = cyclophosphamide; G-CSF = granulocyte colony-stimulating factor; WBC = white blood cell count.
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harvest was temporally associated with reactiva-
tion of herpes zoster virus. Therefore, we believe
that the cause of poor PBSC mobilization in the
first session may have been associated with viral
reactivation.
The risk of viral infection or reactivation is
high among patients with impaired cell-mediated
immunity. However, most of the studies focus on
post-transplant analysis, and the impact of viral
infection on the efficacy of PBSC harvest is un-
known. Viral infection may cause a variable degree
of bone marrow suppression. The causes include
a direct cytotoxic effect on marrow cells, stimula-
tion of the immune response through activation
of cytotoxic lymphocytes or expression of viral
proteins, or an influence on marrow stromal cells
to compromise the bone marrow microenviron-
ment.7 Nevertheless, although the mechanism of
PBSC mobilization is not fully understood, the
complex interplay between adhesion molecules,
chemokines, cytokines, proteolytic enzymes, and
stromal cells is involved in PBSC mobilization.6,8,9
It is possible that the inflammatory cytokines with
their negative effect on proliferation of hemato-
poietic stem cells play a role in poor mobilization
at the time of herpes virus infection.10,11 Further
study is necessary to explore the linkage between
viral infection and its effect on PBSC mobilization.
To resolve the problem of poor mobilization,
remobilization with marrow harvest, a higher
dose of G-CSF, other chemotherapy or growth
factor combination regimens, newly developed
agents such as AMD3100, used alone or in com-
bination with G-CSF or chemotherapy, has been
reported.2,6,8,9 What to use for a repeat mobiliza-
tion attempt for a specific patient and disease may
be a complex decision. The interval between mo-
bilization and remobilization is also crucial.12,13
Our experience suggests that remobilization
with the same regimen (cyclophosphamide and
G-CSF) is feasible when the cause of poor mobi-
lization is associated with herpes zoster virus re-
activation and, possibly, other viral infections.
In conclusion, we presented a case of poor
PBSC mobilization that might have been associ-
ated with reactivation of herpes zoster virus during
the neutropenic phase of mobilization chemother-
apy, and showed the feasibility of remobilization
with the same regimen. However, further study is
necessary to examine the association between
viral infection and PBSC mobilization.
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